(Total Views: 654)
Posted On: 05/14/2024 11:25:54 AM
Post# of 148870
If anyone should ask you what the chance is that CYDY will hit a price of 300 a share,
Update from my friend ChatGpt4
The latest updates on Leronlimab indicate significant progress in its clinical trials and regulatory status. On February 29, 2024, the FDA lifted the clinical hold on Leronlimab, which allows CytoDyn to proceed with its HIV clinical trials. This is a crucial development as it enables further exploration of Leronlimab's effects on chronic inflammation and other potential therapeutic areas (CytoDyn Inc.) (Clinical Trials Arena).
Additionally, CytoDyn has received a positive response from the FDA regarding its Phase 3 registrational trial for critically ill COVID-19 patients. Leronlimab is being investigated for its effects on post-acute sequelae of SARS-CoV-2 (PASC), commonly known as long COVID, and other conditions like NASH (nonalcoholic steatohepatitis), where it showed promising pre-clinical results in reducing liver fibrosis and NAFLD (nonalcoholic fatty liver disease) (Business Wire).
The company also completed a Phase 2 basket trial for Leronlimab in multiple cancer types, which showed increases in the Phase Transition Success Rate (PTSR) for several cancer indications, including glioblastoma multiforme, throat cancer, and bladder cancer (Clinical Trials Arena).
Overall, CytoDyn is actively pursuing multiple avenues to advance Leronlimab's development across various therapeutic areas, reflecting a robust pipeline and ongoing efforts to address unmet medical needs (CytoDyn Inc.) (Business Wire) (Clinical Trials Arena).
Update from my friend ChatGpt4
The latest updates on Leronlimab indicate significant progress in its clinical trials and regulatory status. On February 29, 2024, the FDA lifted the clinical hold on Leronlimab, which allows CytoDyn to proceed with its HIV clinical trials. This is a crucial development as it enables further exploration of Leronlimab's effects on chronic inflammation and other potential therapeutic areas (CytoDyn Inc.) (Clinical Trials Arena).
Additionally, CytoDyn has received a positive response from the FDA regarding its Phase 3 registrational trial for critically ill COVID-19 patients. Leronlimab is being investigated for its effects on post-acute sequelae of SARS-CoV-2 (PASC), commonly known as long COVID, and other conditions like NASH (nonalcoholic steatohepatitis), where it showed promising pre-clinical results in reducing liver fibrosis and NAFLD (nonalcoholic fatty liver disease) (Business Wire).
The company also completed a Phase 2 basket trial for Leronlimab in multiple cancer types, which showed increases in the Phase Transition Success Rate (PTSR) for several cancer indications, including glioblastoma multiforme, throat cancer, and bladder cancer (Clinical Trials Arena).
Overall, CytoDyn is actively pursuing multiple avenues to advance Leronlimab's development across various therapeutic areas, reflecting a robust pipeline and ongoing efforts to address unmet medical needs (CytoDyn Inc.) (Business Wire) (Clinical Trials Arena).
(12)
(0)Scroll down for more posts ▼
